A roundtable of pharmaceutical industry executives discussed the survey findings, alongside the key challenges affecting the pharmaceutical industry. The discussion enabled industry experts to identify the potential for generating savings and improving trial efficiency, as well as assessing how digital disruption is forcing change.
The challenges most frequently cited by survey respondents are patient enrolment (56%), site start-up (43%) and regulatory approval delays and changes (43%). Respondents also identified study start up, patient recruitment and retention, and protocol development as three key areas with the most potential for generating savings and efficiencies.
"ICON recognizes the challenges our customers are facing and is focused
on building our integrated site and patient network to improve trial
start up, as well as patient recruitment and retention." commented Dr.
Opinions of which technology trends will have the greatest impact on clinical trial operations varied. 36% of survey respondents noted that leveraging big data and AI technologies would have the most impact on improving clinical trial efficiency. 35% reported that risk-based approaches toward monitoring held greater opportunity for impact on clinical development.
The survey demonstrates that industry have realised the need for a holistic effort to transform trials, however, only one in five survey respondents (22%) stated their organisation currently has an integrated effort to drive clinical trials transformations. A further 83% of respondents believe strategic partnerships with CROs will be important to the success of clinical trials over the next five years.
Informed by the survey responses, the Improving Pharma R&D Efficiency whitepaper proposes a three-part framework for guiding strategy in transforming clinical trials.
The whitepaper argues that while adopting disparate tactics can improve elements of clinical trial efficiency, the potential is even greater when change is applied in a coordinated fashion to reimagine and reinvent the R&D enterprise.
For further information on ICON's Transforming Trials initiative and the Improving Pharma R&D Efficiency whitepaper, please visit: www.iconplc.com/pharma
About the ICON Transforming Trials survey
Designed, conducted and analysed by Informa Engage using accepted market
research methods, 76 members of the Pharma Database responded to the
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
ICON Media Contact
+44 (0)207 067 0557
News Provided by Acquire Media